Biohaven's Nurtec-less pipeline takes another gut punch,
fails ALS trial
Biohaven failed its second clinical trial since the company sold off its migraine franchise to Pfizer back in May. The company's ALS treatment verdiperstat didn't improve symptoms over placebo.
No comments:
Post a Comment